What is Vor Biopharma's market cap?

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel fusion protein therapies for autoimmune diseases. The company's core value proposition centers on telitacicept, a dual BAFF/APRIL inhibitor designed to modulate the cytokine environment sustaining autoreactive B cells and plasma cells. By targeting these upstream drivers, the company aims to provide deeper and more durable disease control for chronic conditions like generalized myasthenia gravis and Sjögren’s disease.

Competitive position

A clinical-stage developer leveraging a dual-pathway inhibition mechanism with an in-licensed asset already approved in China for multiple indications.

GeographiesUnited States, Europe, Japan, South America, Asia

Customer segmentsRare disease patients, Autoimmune disease patients

Business modelR&D intensive, Licensing and royalties, Biotechnology drug development

SuppliersContract manufacturing organizations (CMOs), Raw material suppliers, Clinical research organizations (CROs), Intellectual property licensors

CustomersSpecialty pharmacies, Hospitals, Infusion centers, Government and private health insurers

CountryUnited States of America

Listed2021

Employees168.0

CEOJean-Paul Kress

SectorHealthcare

IndustryBiotechnology

Websitevorbio.com

FilingsSEC EDGAR

Questions, answered.

What is Vor Biopharma's market cap?: Vor Biopharma (VOR) has a market capitalization of $1.1B and trades on NASDAQ.
Who are Vor Biopharma's competitors?: Vor Biopharma's key competitors include Alexion, Amgen, Argenx, and others. These companies compete in similar markets and product categories.
Who does Vor Biopharma partner with?: Vor Biopharma's notable partners include RemeGen Co., Ltd., TCGX.
Where is Vor Biopharma headquartered?: Vor Biopharma is headquartered in United States of America and employs approximately 168 people. It has been publicly traded since 2021.